Published by
@ShahidNShah
@ShahidNShah
EarliTec Diagnostics Raises $19.5M to Advance Autism Diagnosis and Treatment in Children
EarliTec Dx raises $19.5M for products for children with Autism Spectrum Disorder (ASD) and early childhood vulnerabilities,
This round of financing will be used to support filing with the U.S. Food and Drug Administration (FDA) for 510K clearance, as well as commercialization of the company’s first product, the EarliPoint® Evaluation for ASD, which received breakthrough status in April 2021.
With technology developed by leading researchers at Children’s Healthcare of Atlanta, Emory University School of Medicine and Yale University, the company has completed clinical trials with more than 1,500 children—receiving breakthrough status for the EarliPoint® system in April of last year.
Continue reading at hitconsultant.net
Make faster decisions with community advice
- Helping Clinical Trial Sites Improve Study Recruitment and Retention
- How healthcare organizations are driving technological innovation in 2022
- IT transformations should be guided by improving clinical outcomes
- Industry Voices—Let’s restore frontliners’ personal achievement
- Dispelling the mysteries around neural networks in healthcare
Next Article
-
Helping Clinical Trial Sites Improve Study Recruitment and Retention
It’s no secret that research studies and clinical trial sites struggle with recruitment. In recent years, the pharma industry has supported a more ‘patient-centered’ approach to clinical trial …
Posted Feb 21, 2022 Hybrid Clinical Trial
